You just read:

Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

News provided by

Therapix Biosciences Ltd

07 Feb, 2018, 13:30 GMT